Cantor Fitzgerald Estimates Precigen FY2026 Earnings

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Precigen in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst J. Kim expects that the biotechnology company will post earnings of $0.11 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share.

Precigen (NASDAQ:PGEN - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The company had revenue of $1.34 million during the quarter, compared to analyst estimates of $0.50 million. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%.

Other equities analysts have also issued research reports about the company. JMP Securities reiterated a "market outperform" rating and issued a $6.00 target price on shares of Precigen in a research note on Thursday. Wall Street Zen cut shares of Precigen from a "hold" rating to a "sell" rating in a research note on Saturday, May 24th. Finally, HC Wainwright restated a "buy" rating and issued a $6.00 price objective on shares of Precigen in a research note on Thursday, March 20th.

Precigen Stock Performance

NASDAQ:PGEN traded up $0.05 during trading hours on Wednesday, reaching $1.55. The company's stock had a trading volume of 502,733 shares, compared to its average volume of 1,340,552. The stock has a 50 day moving average price of $1.41 and a two-hundred day moving average price of $1.36. The company has a market capitalization of $457.53 million, a P/E ratio of -2.82 and a beta of 1.85. Precigen has a 12 month low of $0.65 and a 12 month high of $2.17.

Hedge Funds Weigh In On Precigen

Hedge funds have recently made changes to their positions in the company. Parkman Healthcare Partners LLC acquired a new stake in Precigen during the 1st quarter worth $4,755,000. Adage Capital Partners GP L.L.C. grew its stake in Precigen by 3.8% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 11,276,000 shares of the biotechnology company's stock valued at $16,801,000 after acquiring an additional 410,595 shares in the last quarter. Inspire Investing LLC purchased a new stake in Precigen during the 1st quarter valued at about $350,000. Nuveen LLC acquired a new stake in Precigen in the 1st quarter valued at about $275,000. Finally, Mill Creek Capital Advisors LLC lifted its stake in Precigen by 131.8% in the 1st quarter. Mill Creek Capital Advisors LLC now owns 255,000 shares of the biotechnology company's stock worth $380,000 after purchasing an additional 145,000 shares in the last quarter. Institutional investors and hedge funds own 33.51% of the company's stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.